Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R. Adkins, Makoto Tahara, Nataliia Komashko et al.|Oral Oncology|2021Cited by 43
Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).Douglas R. Adkins, Makoto Tahara, Jin‐Ching Lin et al.|Journal of Clinical Oncology|2019Cited by 18
Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysisMakoto Tahara, Douglas Adkins, Jin Lin et al.|Annals of Oncology|2019Cited by 0